Abstracts

Rosenstock study and other two RCTs compared Glargine to Determin showed Glargine and Determin has no difference in HbA1c control and hypoglycemia rate for the patient with type 2 diabetes. Based on the Rosenstock study, cost-minimization study was performed. Mean daily dexter dose was higher (0.78 U/kg [0.32 with once daily dose, 1.00 U/kg with twice daily dosing]) than glargine (0.44 U/kg) and direct cost was estimated from the perspective of the health insurance. The time horizon was one year of treatment. The price was refered to Price in 2008. The currency is Yuan. The cost of insulin medication (glargine or determir) and consum- able items (needles and glucose test strips) was included as the direct cost. In case of sensitivity analysis on resource use and unit costs around base case parameters was performed to test the robustness of the base case results RESULTS: Insulin glargine was associated with 40.77% ($8949.35/pers per year) saving compared to determining glargine. The difference in cost was approximately the same in different countries. The results suggest that the price of determir is lower in China. Univariate sensitivity analysis on resource use and price in Determin has been performed and confirmed the robustness of the results in favor of insulin glargine in China. The current study findings are consistent with the direction magnitude of cost saving reported in Spain, Hungary, Argentina, Germany and UK. CONCLUSIONS: Insulin glargine was cost saving compared to insulin determir in China. The information is important for health care providers who are considering the total budget for the type 2 DM patient with basal insulin.

PDB35 COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLITIN VS. METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN ARGENTINA

Eigart J1, Caporale F1, Guglierdano J1, Alcalde EC2, Wahabshah M1, Jattumajorn L1,1 National University of La Plata, La Plata, Buenos Aires, Argentina, National University of La Plata, La Plata, Pro. De Bs As, Argentina, Bristol-Myers Squibb, Buenos Aires, - Argentina, Bristol-Myers Squibb, Buenos Aires, Argentina

OBJECTIVES: To determine the cost-effectiveness ratio of adding saxagliptin to metformin therapy (SAXA+MET) compared to adding sulfonylureas (SULF+MET), in patients with type 2 diabetes mellitus (DM2) who have failed to achieve adequate glycemic control with metformin. METHODS: A discrete event simulation model (Cardiff Long term cost-utility model) based on UKPDS 68 with a fixed time increase was used to simulate disease progression and to obtain an estimate of the treatment's economic and health consequences in DM2 patients. The clinical efficacy parameters for saxagliptin were obtained from the literature; drug acquisition costs, adverse effects (AEs) and macrovascular and microvascular complications were taken into account. Costs were expressed in United States dollars (2009), with an annual 3.5% discount. The time horizon was 20 years. RESULTS: A lower number of non-fatal events was found for the SAXA+MET-treated group versus the SULF+MET-treated group. Additionally, the model predicted a lower number of fatal events for macrovascular (146 vs. 151) and microvascular (17.7 vs. 17.9) events for the SAXA+MET-treated group vs. the SULF+MET-treated group. The total cost of the SAXA+MET cohort was 14% higher than that of the SULF+MET cohort. Treatment with SAXA+MET resulted in a higher number of QALYs (9.392 vs. 9.172) and LYs (20.898 vs. 20.797) than treatment with SULF+MET; the additional cost per QALY and LY gained was US$6,691 and US$ 14,656 respectively. CONCLUSIONS: Considering the GDP per capita in Argentina, results suggest that the addition of saxagliptin to metformin therapy should be made because it will result in a statistically significant decrease in cardiovascular events and macrovascular and microvascular complications, thereby yielding a cost-effectiveness ratio in DM2 patients in Argentina.

PDB36 ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT)

Gan H1, Bell C2, Bottamini P3, Van Hout BA4 1Pharmerit North America, LLC, Bethesda, MD, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3University of Sheffield, Sheffield, UK

OBJECTIVES: To assess the impact of PDPN/PHN-related health impairment on LOPT in patients treated with chronic PDPN/PHN. METHODS: Using data from 777 employed adults with ≥3 months of PDPN/PHN and receiving pain medications, the effect of PDPN/PHN-related impairment on LOPT was estimated by: 1) single equa- tion probit models (SEPM) assuming pain severity was exogenous, adjusting for respondents’ social isolation and psychological distress. Its relationship with LOPT appears only significant when accounting for the GDP per capita in Argentina, results suggest that the addition of saxagliptin to metformin therapy should be made because it will result in a statistically significant decrease in cardiovascular events and macrovascular and microvascular complications, thereby yielding a cost-effectiveness ratio in DM2 patients in Argentina.

PDB37 THE IMPACT OF DIABETES ON WORKPLACE ABSENTEEISM AND PRESENTEISM: A COMPARISON OF CHINA AND JAPAN

Langley PC1, Stankus KA2, Annunziata K2, Gross H3 1University of Minnesota, Minneapolis, MN, USA, 2Kantar Health, Princeton, NJ, USA

OBJECTIVES: The purpose of this study is to consider the extent to which estimates of the impact of diabetes on employment status, absenteeism and presenteeism varies between China and Japan. METHODS: Data from the 2008 and 2009 National Health and Wellness Surveys undertaken in Japan and urban China were used to estimate a logistic employment status model and ordered probit regression analyses of the determinants of absenteeism and presenteeism for those employed full-time, part-time or self employed. Absenteeism was determined by respondents indicating time off due to ill health in the past seven days; presenteeism was determined by respondents assessing the extent to which workplace productivity was impacted by their health status in the same time period. Apart from diabetic status the models included demographic and socio-economic characteristics, the Charlson Comorbidity Index, together with health risk factors and controls for absenteeism experience and diagnosed diabetes. RESULTS: In both China and Japan a diagnosis of diabetes was found to have a significant (1% level) negative impact on employment status (odds ratios 0.340 and 0.796 respectively). The results for absenteeism point once again to the significant (at 1% level) positive impact of diabetes on higher rates of absenteeism with odds ratios of 1.037 for China but only 1.140 respectively for Japan. The cost of presenteeism the impact of diabetes is still significant (1% level) in the case of China, but less so for Japan (odds ratios 2.102 and 1.179 respectively). CONCLUSIONS: The presence of diabetes has a significant and negative impact on workforce status as well as on absenteeism in China and Japan. Both countries show similar impacts, although in Japan the impact on presenteeism is less marked.

PDB38 THE IMPACT OF DIABETES ON WORKPLACE PRESENTEISM: A CROSS NATIONAL STUDY IN THE EUROPEAN UNION

Langley PC1, Annunziata K2 1University of Minnesota, Minneapolis, MN, USA, 2Kantar Health, Princeton, NJ, USA

OBJECTIVES: The purpose of this study is to consider the extent to which estimates of the impact of diabetes on presenteeism can vary between major industrial countries and to assess the relative contribution of absenteeism, socio-demographic and health risk factors. METHODS: Data from the 2008 National Health and Wellness Survey, a national survey of five EU countries (the UK, France, Spain and Italy) were used to estimate an ordered probit regression analysis of the determinants of presenteeism for those employed full-time, part-time or self employed. Presenteeism was deter- mined by respondents assessing the extent to which workplace productivity was impacted by their health status on a 10-point scale. The model includes health risk factors (BMI, alcohol use, smoking), the Charlson Comorbidity Index (CCI) along with controls for absenteeism experience and diagnosed diabetes. RESULTS: Absen- teeism, the percentage of time lost in the previous seven days, was the dominant factor impacting presenteeism for all countries (odds ratios 16.17 Germany to 9.23 Italy). With the exception of Spain, obesity and morbid obesity had a positive and significant impact with odds ratios in the range 1.33 – 1.04 and 2.08 – 1.60 respectively. The presence of diabetes was significant for all countries with odds ratios ranging from 1.29 (Italy) to 1.77 (Spain). Replacing diabetes with the CCI resulted in significant odds ratios in the range 1.33 (Germany) to 1.17 (UK). CONCLUSIONS: The presence of diabetes has a significant and negative impact on workplace presenteeism. The impact of diabetes is of a similar order of magnitude to the presence of obesity and morbid obesity.

DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies

PDB41 BELIEFS AND EXPECTATIONS ABOUT DIABETES AND MEDICATION ADHERENCE IN PERSONS WITH TYPE 2 DIABETES

Jr. S, Thomas J 1Western Michigan University, West Lafayette, IN, USA

OBJECTIVES: Associations between type 2 diabetic patients’ beliefs and expectations about their illness and medication adherence were determined. METHODS: A cross- sectional self-administered written survey of type 2 diabetes patients was conducted in an outpatient’s food pharmacy at a hospital serving an urban population. Study inclusion criteria were being 18 years or older, diagnosed with type 2 diabetes at least 6 months prior to the time of the survey, and taking oral anti-diabetic medication. Exclusion criteria were use of insulin or not being able to read and write in English. The survey included the Brief Illness Perception Question- naire (B-IPQ) to assess individuals’ illness beliefs and the Morisky 8-item Medication Adherence Scale to collect self-reported adherence. Chi-square tests of association and Pearson correlation analysis were used to assess whether illness beliefs were associated with measures of medication adherence. RESULTS: Two thirds of the sample (72%) had annual household income of less than $25,000. A majority (56%) reported ideas about how this impact is mediated by respondents’ social isolation and psychological distress. Alternative IVs for adjusting endogeneity bias of pain severity are worth exploring.